RxDoctor Payments Data

Steven Bui, MD

Nephrology · Garden Grove, CANPI 1154390425

Payments from drug & device makers

$361,974in general payments, 2019–2025

Across 78 payments — averaging $4640.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$360K
  • AstraZeneca$636
  • Otsuka America Pharmaceutical, Inc.$468
  • Akebia Therapeutics Inc$169
  • Travere Therapeutics, Inc.$95
  • Bayer$85
  • plus $113 from 4 others

What the payments were for

  • Food & beverage$1,50696%
  • Education$614%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$361,974 in reported general payments places this provider in the 90th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$317,894
Medicare patients
444
Services billed
2,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol78$58,944
KerendiaFinerenone39$28,694
Sevelamer Carbonate68$16,592
JanuviaSitagliptin Phosphate17$10,352
ProsolParenteral Amino Acid 20% No.155$9,950
LokelmaSodium Zirconium Cyclosilicate25$9,771
EliquisApixaban14$7,797
RetacritEpoetin Alfa-Epbx16$6,909
ClinolipidFat Emulsion/Olive/Soy/Phospho14$3,695
Calcium Acetate45$3,091
Febuxostat22$1,738
Lisinopril143$893
Metoprolol Succinate78$880
Amlodipine Besylate199$815
Clonidine Hcl46$607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$636$68,715103 claims
BayerKerendia$85$28,69439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,341 nephrology providers in California.

Other nephrology in Garden Grove

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →